GUTS (Fractyl Health Inc.) Earnings per share for the last four quarters

Fractyl (GUTS) - corporate logo

This chart confirms the market price reflects EPS (TTM) dynamics at 79.70. Fractyl Health, Inc. (GUTS) integrates gene therapy with endoscopic methods to combat diabetes. The company is developing partnerships with endocrinologists to improve treatment precision. The current strategic trajectory focuses on the commercial launch of innovations and securing US regulatory approvals for obesity therapy.

GUTS fractyl.com Net earnings per share (EPS TTM) (11/23/2025 - 11/17/2026)

GUTS (Fractyl Health, Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:GUTS (Fractyl Health Inc.)
Core merchandise of Fractyl Health, Inc

The combination of medical device development and gene therapy at Fractyl Health, Inc. (GUTS) mitigates regulatory risks, which directly impacts profit dynamics. By analyzing the annual change in net income per share over a rolling period on GURU.Markets, an investor assesses the growth rates of real earnings per share, determining the business's ability to generate value amid the Federal Reserve's tight monetary policy.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Net earnings per one share for the last twelve months|SLNO - Earnings per share for the last twelve months|FOLD: Earnings per share for the last twelve months|ETNB: Net earnings per share (EPS TTM)|AGIO - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months rezolutebio.com (RZLT)|Net earnings per share for the last 12 months lexpharma.com LXRX|Net earnings per share (EPS TTM) MBX (MBX Biosciences)|Altimmune Corp - Earnings per share for the last twelve months|Aardvark Therapeutics Inc. - Net earnings per share (EPS TTM)|SGMT - Net earnings per share (EPS TTM)|BioAge Labs (BIOA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months biomeafusion.com (BMEA)|Earnings per share for the last twelve months Quince Therapeutics, Inc.|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS